Neurological disorders impacting cognition and memory, such as schizophrenia and Alzheimer's disease, afflict millions of Americans. The search for factors involved in neurological disorders has identified disruptions in a fundamental neuronal process, synaptic plasticity, in nearly all pervasive neurological disorders. Synaptic plasticity, widely held to be the cellular substrate of memory, describes the specific modification of neuronal connections in response to experience. Thus, altered mechanisms controlling this process may be causal in the pathophysiology of patients suffering neurological dysfunction. One mechanism thought to play an important part in synaptic plasticity, with an increasingly important role in schizophrenia, intellectual disability and neurodegenerative diseases, is the Akt signaling pathway. Three isoforms of Akt (Akt1/PKB?, Akt2/PkB?, and Akt3/PKB?) are expressed in the brain, and they display some overlapping function but are also known to have distinct physiological roles in organs including the brain. The role played by the different Akt isoforms in synaptic plasticity processes is unknown. This is an important problem to overcome because improved understanding of Akt function in synaptic mechanisms, especially the role of the different isoforms, will allow for improved diagnoses and therapies aimed at treating neurological disorders. Therefore, the main hypothesis driving this proposal is that Akt isoforms are differentially recruited for neuromolecular signaling underlying synaptic plasticity, cognition and memory formation.
The aims of this proposal are to (1) test the hypothesis that Akt isoforms differentially regulate the expression of long-term potentiation (LTP) in the hippocampus, (2) test the hypothesis that Akt isoforms differentially regulate the expression of different forms of long-term depression (LTD) in the hippocampus, (3) test the hypothesis that different Akt isoforms play specific roles in behavior and memory formation. To test these aims, we will use novel pharmacological agents that target pan-Akt and isoform-specific activity, enabling us to modulate Akt function in vivo. To complement this approach, we will also genetically probe the role of Akt in synaptic function, cognition, and memory using Akt mutants. These combined approaches will be applied to electrophysiological, biochemical, and behavioral analyses for examining synaptic plasticity, protein synthesis and behavioral performance in mouse models of neurological disorders. Our approach is conceptually and technically innovative because we will utilize novel pharmacological, genetic, and viral reagents to specifically target Akt isoform function in synaptic processes and behavior. This proposed research is significant because it addresses fundamental questions about the differentiation of neurobiological signaling involved in cognition, which has important implications for mental health. By defining Akt isoform-specific regulation of synaptic plasticity and cognition, our approach will provide new insight into Akt-dependent mechanisms affected in neurological diseases and psychiatric disorders associated with cognitive impairments.

Public Health Relevance

The proposed research is relevant to public health because the identification of cellular mechanisms that promote or increase the severity of human neurological disorders may be used to create new diagnoses for the onset of neurological disease, develop new treatments against diseases, and determine the efficacy of ongoing therapies directed against a disease. As such, the proposed research examining the role of different Akt isoforms in synaptic plasticity, cognition, and memory formation is relevant to the part of the NIH's mission that pertains to developing basic scientific knowledge in the causes, diagnosis, prevention, and cure of human diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS086933-04
Application #
9453041
Study Section
Synapses, Cytoskeleton and Trafficking Study Section (SYN)
Program Officer
Churn, Severn Borden
Project Start
2015-04-01
Project End
2020-03-31
Budget Start
2018-04-01
Budget End
2019-03-31
Support Year
4
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Colorado at Boulder
Department
Genetics
Type
Graduate Schools
DUNS #
007431505
City
Boulder
State
CO
Country
United States
Zip Code
80303
Wong, Helen; Hoeffer, Charles (2018) Maternal IL-17A in autism. Exp Neurol 299:228-240
Levenga, Josien; Wong, Helen; Milstead, Ryan A et al. (2017) AKT isoforms have distinct hippocampal expression and roles in synaptic plasticity. Elife 6:
Ostroff, Linnaea E; Botsford, Benjamin; Gindina, Sofya et al. (2017) Accumulation of Polyribosomes in Dendritic Spine Heads, But Not Bases and Necks, during Memory Consolidation Depends on Cap-Dependent Translation Initiation. J Neurosci 37:1862-1872
Koukouli, Fani; Rooy, Marie; Tziotis, Dimitrios et al. (2017) Nicotine reverses hypofrontality in animal models of addiction and schizophrenia. Nat Med 23:347-354
Congdon, Erin E; Lin, Yan; Rajamohamedsait, Hameetha B et al. (2016) Affinity of Tau antibodies for solubilized pathological Tau species but not their immunogen or insoluble Tau aggregates predicts in vivo and ex vivo efficacy. Mol Neurodegener 11:62
Choi, Gloria B; Yim, Yeong S; Wong, Helen et al. (2016) The maternal interleukin-17a pathway in mice promotes autism-like phenotypes in offspring. Science 351:933-9
Wong, Helen; Levenga, Josien; Cain, Peter et al. (2015) RCAN1 overexpression promotes age-dependent mitochondrial dysregulation related to neurodegeneration in Alzheimer's disease. Acta Neuropathol 130:829-43